Bayer Aktiengesellschaft (BAYZF)
OTCMKTS
· Delayed Price · Currency is USD
25.49
+0.18 (0.71%)
Mar 10, 2025, 4:00 PM EST
Bayer Aktiengesellschaft Revenue
In the year 2024, Bayer Aktiengesellschaft had annual revenue of 46.61B EUR, down -2.16%. Bayer Aktiengesellschaft had revenue of 11.73B in the quarter ending December 31, 2024, a decrease of -1.12%.
Revenue
46.61B EUR
Revenue Growth
-2.16%
P/S Ratio
n/a
Revenue / Employee
480.82K EUR
Employees
96,931
Market Cap
25.37B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 46.61B | -1.03B | -2.16% |
Dec 31, 2023 | 47.64B | -3.10B | -6.11% |
Dec 31, 2022 | 50.74B | 6.66B | 15.10% |
Dec 31, 2021 | 44.08B | 2.68B | 6.48% |
Dec 31, 2020 | 41.40B | -2.15B | -4.93% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.79B |
SS Innovations International | 16.04M |
Veradigm | 1.53B |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 188.29M |
Northwest Biotherapeutics | 1.60M |
Silence Therapeutics | 43.26M |
BioStem Technologies | 210.49M |
Bayer Aktiengesellschaft News
- 23 hours ago - Bayer share drop draws scrutiny from market regulator - Reuters - Seeking Alpha
- 1 day ago - Exclusive: Bayer share drop draws market regulator's scrutiny, source says - Reuters
- 4 days ago - Bayer told analysts of cash call plan a day before official statement - Reuters
- 4 days ago - Bayer shares plunge 10% as ongoing U.S. lawsuits trigger cash-raising plans - Fortune
- 4 days ago - Bayer seeks clearance to raise capital as conglomerate battles legal claims - Financial Times
- 5 days ago - Bayer to run glyphosate as a ‘separate business’ - EURACTIV.com
- 5 days ago - Bayer seeks OK for potential capital raise over Roundup legal troubles - Seeking Alpha
- 5 days ago - Bayer seeks investor approval for 35% cash call to gird for litigation - Reuters